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Thedefinition of posttranslationalmodification (PTM) encompasses awide group of chemical reactions that allowmodification and
modulation of protein functions.The regulation of PTMs is crucial for the activity and survival of the cells. Dysregulation of PTMs
has been observed in several pathological conditions, including rheumatoid arthritis (RA). RA is a systemic autoimmune disease
primarily targeting the joints. The three PTMs mainly involved in this disease are glycosylation, citrullination, and carbamylation.
Glycosylation is essential for antigen processing and presentation and can modulate immunoglobulin activity. Citrullination of
self-antigens is strongly associated with RA, as demonstrated by the presence of antibodies directed to anti-citrullinated proteins
in patients’ sera. Carbamylation and its dysregulation have been recently associated with RA. Aim of this review is to illustrate the
most significant alterations of these PTMs in RA and to evaluate their possible involvement in the pathogenesis of the disease.
1. Introduction
Human cells are able to maintain high levels of efficiency
and organization thanks to a complex and finely regulated
network of numerous processes (e.g., DNA transcription,
protein synthesis). The proper managing of these processes
strictly depends on a large group of chemical reactions named
posttranslational modifications (PTMs). A PTM consists in
every change of chemical structure or property of a protein
that occurs after or at the same time of its translation.
Nowadays, over 300 PTMs are known [1] and over 200 of
them are enzyme-mediated [2], highlighting the attempt of
the cell to exploit these modifications for surviving. PTMs
are crucial for the development and evolution of every living
organism, and it is universally accepted that the more the
species are advanced, the better they use and organize PTMs
[3]. PTMs and their dysregulations in pathological conditions
gained great interest, due to the continuous improvement
in biotechnologies that allow better investigation of and
definition of these processes.
Rheumatoid arthritis (RA) is an autoimmune disease
affecting about 1% of the general population and it is charac-
terized by polyarticular, symmetric involvement of synovial
joints, as well as several extra-articular manifestations, such
as rheumatoid nodes, pulmonary fibrosis, and accelerated
atherosclerosis [4]. The pathogenesis of RA has not been
completely elucidated yet and although in these last decades
the use of new therapeutic agents has improved the prognosis
of the disease, RA is still an important cause of morbidity and
disability.
The aim of this review is to give an overview on the role
of PTMs in the pathogenesis of RA, focusing on the modi-
fications that have been strongly associated with the disease:
glycosylation, citrullination, and carbamylation (Table 1).
2. Glycosylation in Rheumatoid Arthritis
Glycosylation consists in the addition of sugars on nitrogen
(N-glycosylation) or oxygen (O-glycosylation) atoms of the
side chain of the protein amino acids. This reaction is
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2015, Article ID 712490, 10 pages
http://dx.doi.org/10.1155/2015/712490
2 Journal of Immunology Research
Table 1: Summary of some posttranslational modifications in rheumatoid arthritis.
PTM Effect(s) Reference
Glycosylation: PTM that consists in the
addiction of glucides on an atom of
nitrogen (N-glycosylation) or oxygen
(O-glycosylation) of the lateral chain of
the amino acids that forms a protein.
Epitopes presentation:
-Protein glycosylation interacts with the processes of
antigen presentation.
-These interactions regard both antigen processing
pathways in APCs and TCR-MHC II complex formation.
Haurum et al., 1999 [6]
Jefferis et al., 1995 [22]
Igs properties:
-Fc fragment of immunoglobulins has an important site of
N-glycosylation, the asparagine 297 (Asn297).
-It has been shown that IgG can have both
proinflammatory and anti-inflammatory activity,
depending on which Fc𝛾 receptor they preferentially bind
to: those different affinities for receptors are strictly
dependent on the composition of the saccharine lateral
chain linked to Asn297.
Goulabchand et al., 2014
[23]
Citrullination: PTM consisting in the
switch of the imine nitrogen of an
arginine to an atom of oxygen, linked to
the backbone structure as a ketone. It is
mediated by a family of enzymes called
PAD (or PADI).
-It is associated with histone modification, genomic
regulation and NET formation.
-PAD activation can be an intracellular or extracellular
event, due to various conditions. -This activation can lead
to the creation of altered self-epitopes and ACPA
formation.
Yamada et al., 2005 [49]
Khandpur et al., 2013
[60]
Carbamylation: Nonenzymatic PTM that
consists in the addiction of a cyanate
group on proteins.
-Loss of the native proteic structure. This event can lead to
a break of tolerance and finally results in the formation of
anti-CarP autoantibodies.
Shi et al., 2011 [90]
ACPA: anti-citrullinated protein antibodies; anti-CarP: anti-carbamylated protein; APC: antigen presenting cell; NET: neutrophil extracellular trap; PAD:
peptidylarginine deiminase; PTM: posttranslational modification.
mediated by hundreds of glycosyl-transferases (GTs), regu-
lated basically at transcriptional level. Human cells modify
simple sugars, such as glucose or galactose, in more complex
ones, in order to create a larger number of precursors for
glycosylation; subsequently, the linking of uridine diphos-
phate or, rarely, cytosinemonophosphate activates the sugars.
Glycosylation occurs on both extracellular and intracellular
proteins and it is crucial for several vital processes such as
proteins folding or cell-to-cell interactions [5]. Glycosylation
is involved in two physiopathological processes—epitope
presentation to immune system and immunoglobulins- (Igs-)
mediated regulation of immune response—suggesting a pos-
sible association of aberrant glycosylation with RA (Figure 1).
Furthermore, aberrant glycosylation of different plasma pro-
teins was demonstrated in RA patients.
2.1. Glycosylation and Epitope Presentation. Glycosylation
affects the antigen presentation acting both on antigen
processing pathways in antigen presenting cells (APCs) and
on T cell receptor- (TCR-) MHC II complex formation.
Glycosylation plays an important role in antigen pre-
sentation by modifying the cleavage of proteins in both
proteasome (MHC I-associated pathway) and endosome
(MHC II-associated pathway). A considerable number of
cytosolic peptides presented on MHC I molecules carry an
O-glycosylation with a molecule of N-acetyl-glucosamine
(GlcNAc) [6]. The O-GlcNAcylation is a PTM that interacts
with phosphorylation [7] to regulate several intracellular
processes, such as the activation of nuclear transcription
factors and the responses to nutrient deprivation. Abolishing
or modifying the physiological O-GlcNAcylation processes,
as observed during inflammation or other responses to
stressful stimuli [8], could determine the presentation of new
antigenic glycopeptides onMHC Imolecules that can bind to
autoreactive T cells.
Regarding MHC II-associated pathway, it was demon-
strated that different glycoforms of the same protein are
processed in different ways, generating different peptides
linked on MHC II molecules; this process can lead to
the presentation of cryptic self-antigens or to an enhanced
presentation of normally nonimmunodominant self-antigens
[9].
During the antigen presentation, APCs are not capable of
cleaving the side sugar chains; so, if a certain peptide carries a
glycan side chain, the whole glycan-peptide complex will be
presented onMHC II molecule.This process may improve or
diminishTCRaffinity for theMHC-peptide complex by steric
interference [10].
Glycosylation influences T lymphocyte activation. Many
studies investigated T cell responses to subtypes of collagen
II-derived peptides in mice with collagen induced arthritis
(CIA) [11, 12]. Corthay and coworkers pointed out that the
response to these peptides is strictly dependent on the PTM
carried on lysine 264 (K264). B10.Q mice showed a strong
response to galactosylated K264 and a very weak response to
unmodified or hydroxylated K264 collagen derived peptides
[13]. As expected, mice immunization with galactosylated
K264/MHC II complex reduced the severity of arthritis and
the extent of the humoral [anti-type II collagen (anti-CII)
antibodies] immune response [14]. Recently, Batsalova et al.
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Figure 1: Aberrant glycosylation affects antigen presentation and can induce breaking of tolerance. (Of note, due to the cross-presentation
pathway, intracellular proteins with altered glycosylation could be presented on MHC II molecules to T CD4+).
demonstrated that DR4 transgenic mice (expressing human
HLA-DR4 allele) are more responsive to the unmodified or
hydroxylated K264 compared to the galactosylated one [15].
These results are in accordance with the previous observation
that collagen from human and rats with active arthritis con-
tains glycosylated and unglycosylated zones; on the contrary,
in healthy subjects collagen is uniformly glycosylated [16].
Besides collagen, other proteins—for example, p68—show a
glycosylation-dependent T cell recognition [17]; hence, an
aberrant glycosylation might be one of the triggers for the
onset and progression of RA.
Infections as well lead to an alteration of self-protein
glycosylation. E. coli is able to modify glycosylation of self-
proteins, due to its own GTs expression [18]. H. pylori
CagA toxin could also alter the glycosylation processes in B
lymphocytes [19]. Moreover, the cytokine secretion induced
by these (and other) pathogens is able to modify the cellular
pattern of GTs [20, 21]. All together, these events could be
a rational explanation for the theory of “infection-triggered
autoimmunity.”
2.2. Glycosylation and Immunoglobulin Properties. As pre-
viously mentioned, glycosylation may affect the immune
system also bymodifying IgG properties. Fc fragment of IgGs
has an important site of N-glycosylation, the 297 asparagine
(N297). IgGs can exert both proinflammatory and anti-
inflammatory activities depending on which Fc𝛾 receptor
they preferentially bind: the different receptor affinity strictly
depends on the composition of the sugar side chain linked
to N297 [22, 23]. The phenotype associated with a higher
proinflammatory activity displays low levels of galactose and
sialic acid [24]; differently, the anti-inflammatory phenotype
is characterized by normal galactose and sialic acid and
reduced GlcNAc levels [25, 26]. IgGs can exert their anti-
inflammatory effects also by binding to other receptors:
whether this interaction is dependent or not on Fc fragment
glycosylation is still unclear [27–29]. Different factors, such as
interleukins or lipopolysaccharide, can induce a proinflam-
matory pattern of the sugars linked to IgGs [30, 31]. This
whole process finally leads to a vicious circle of self-sustaining
immune activation.
In active RA, anti-citrullinated peptide antibodies
(ACPA) and rheumatoid factor (RF) display the proinflam-
matory N297 glycosylation pattern, with low levels of gal-
actose and sialic acid [32–34]. These autoantibodies acquire
this glycosylation pattern before the clinical onset of the
disease [35]; interestingly, changes in IgGs glycosylation were
associated with RA remission observed during pregnancy
[36, 37]. Taken together, these observations remark the
crucial role of IgG glycosylation in the pathogenesis of the
disease.
Many circulating proteins can also display an altered
glycosylation in RA [38–40]. For example, lubricin isolated
by synovial fluid of RA patients expresses an aberrant glycan
determinant and shows an L-selectin ligand activity that may
induce the activation of neutrophils and polymorphonuclear
cells [40].
A good response to therapy turns the IgGs glycosylation
back to a noninflammatory phenotype [41]. In order to stop
the vicious circle triggered by the altered IgGs glycosylation,
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Nandakumar et al. proposed a treatment with endostreptosin
(EndoS)—a bacteric glycosidase able to trim the whole
N297 side chain. In vitro incubation of anti-CII monoclonal
antibodies with EndoS prevents the onset of arthritis in
mice; this effect persists even if antibodies-EndoS are injected
together with anti-CII antibodies [42].
Some authors hypothesized a possible treatment of severe
RA and, in general, of autoimmune diseases with sialic acid
enriched-intravenous Igs; however, the preliminary results
are not conclusive and call for further researches [43, 44].
3. Citrullination and Rheumatoid Arthritis
Citrullination is a protein modification consisting in the
switch of the iminic nitrogen of arginine to oxygen, linked to
the backbone structure as a ketone; this process results in the
production of an amino acid called citrulline. The reaction
is mediated by a family of enzymes called peptidylarginine
deiminase (PAD or PADI) [45] (Figure 2). Nowadays, 5
subtypes of PAD (PAD1-6), variously distributed in human
cells, are known [46, 47]. The activity of these enzymes is
regulated by intracellular Ca2+ concentration. The subtypes
of PAD expressed by the immune cells are PAD4 and
PAD2, markedly present in neutrophils and mast cells [48].
The switch from arginine to citrulline has several different
consequences on protein structure: the oxygen of citrulline
is a noncharged atom, differently from the positive-charged
nitrogen of arginine; since side chain charge of the amino
acid sequence is crucial for the protein folding, an alteration
in the electronic milieu modifies the tertiary structure of the
peptide [49]. So far, citrullination is associated with histone
modifications, neutrophils extracellular trap (NET) forma-
tion, and epidermal, central nervous system and skeletal
muscle tropism regulation [47].
Immunogenicity of citrullinated proteins has been stud-
ied, especially in autoimmune diseases such as RA, leading to
the identification of ACPA. Nowadays, ACPA are essential in
RA diagnosis: the presence of these autoantibodies, revealed
with the ACPA assays, has a specificity of 85–95% and a
sensitivity of about 80% [50].
ACPA can be identified in about 50% of RA patients
approximately 1 year before the onset of arthritis [51]. Higher
titre of ACPA at diagnosis is considered a negative prognostic
factor and ACPA titre seems to be reduced after treatment
[52, 53]. Furthermore, citrullinated antigens recognized by
ACPA are abundant in inflamed synovia; among the others,
alpha-1 antitrypsin, fibrinogen, apolipoproteins, histones,
immunoglobulins, and vimentin had been characterized [54].
All these findings depose even for a pathological role of
these autoantibodies in the development of RA.
Two questions arising from these data still remain par-
tially unsolved: why do RA patient antibodies recognize as
“non-self ” the citrullinated proteins? And how citrullinated
antigens are produced?
The first question found a partial answer in the strong
association between ACPA-positive RA and specific HLA
polymorphisms, especially the conserved region of HLA-
DRB1∗0104 allele: subjects who carry this allele have an
higher risk of developing an erosive ACPA-positive RA,
due to the ability of the HLA molecule coded by this
specific haplotype to bind and present citrullinated antigens
[55]. Nevertheless, this haplotype is also diffused in healthy
population. Other susceptibility genes have been identified,
but altogether they represent only 50% of genetic variance
associated with ACPA-positive arthritis [56]. Clearly, more
studies are needed to elucidate the physiopathological path-
way leading to ACPA formation.
The latter question is muchmore complex. In fact, even if
the final step of citrullination always consists in the activation
of the PAD-family enzymes, the modulation of this pathway
is variable and still not completely understood.
Summarizing, the processes leading to the formation
of citrullinated epitopes can result in an accumulation of
citrullinated proteins at extracellular and/or intracellular
levels, which will be subsequentely described.
3.1. Extracellular Accumulation. Extracellular accumulation
of citrullinated proteins is related to two main factors:
NET formation and P. gingivalis infection. NETosis is a
powerful defensivemechanism developed by immune system
in order to trap and destroy extracellular bacteria. NETs
are constituted by loose chromatin complexed with many
antimicrobial enzymes stored in neutrophils granules; this
whole complex is expelled by the cell in the extracellular
space. The negative charge of chromatin traps the bacteria,
allowing the enzymes to kill the microorganisms [57]. To
undergo NETosis, neutrophils need PAD4 activation: the
histone citrullination mediated by this enzyme causes chro-
matin relaxation that is crucial for the subsequent processes
[58]. NETosis has been associated with several pathological
conditions, like thrombosis, multiple sclerosis, and RA [59].
In RA, several alterations in NET formation have been
noticed. When compared to healthy subjects, neutrophils
isolated by the peripheral blood of RA patients undergo
NETosis more easily; NETosis can be induced by RF or
ACPA and, finally, the enzyme load of the chromatin shows
differences betweenNETs of RA patients and healthy subjects
[60].
In an inflammatory contest, such as the rheumatoid
synovia, NETs release citrullinated antigens [61]: in RA
predisposed individuals, synovial citrullinated antigens may
be caught and presented to T lymphocytes, promoting a local
immune response.
P. gingivalis, a Gram negative, nonmotile, anaerobic
bacterium, is considered the major causative agent of peri-
odontitis in humans [62]. Periodontitis is an inflammation
of the structures surrounding the teeth, affecting about 50%
of the adult population [63]. It is also a well-studied risk
factor for the development of RA [64], since P. gingivalis is
the only bacterium able to synthesize its own PAD [65]. This
bacterium can lead to an increase in citrullination of host
periodontium proteins, creating new citrullinated epitopes
[66].
Arandjelovic et al. hypothesized a new pathway for
extracellular citrullination: in vitro, ATP from dying cells
can bind an ATP-receptor on mast cells and promote the
activation and the release in the extracellular space of PAD2
[67].
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Figure 2: Biochemical process that occurs in protein citrullination event.
3.2. Intracellular Accumulation. Severalmechanisms of intra-
cellular accumulation of citrullinated proteins have been
demonstrated in vitro and they represent an interesting field
of research.
Autophagy is a cellular process consisting in the fusion of
lysosomal vacuoles with vacuoles coming from intracellular
elements, in order to digest them and restore energetic
and nutrient reserve. Autophagy plays an important role
in the regulation of intracellular organelle turnover [68].
Physiologically, this process occurs in starvation or under
other stressful conditions for the cell and it has been also
associated with several pathological conditions [69], includ-
ing RA. During amino acid deprivation in B lymphocyte cell
cultures, the induction of autophagy pathways leads to the
intracellular activation of PAD and to the citrullination of
self-peptides occurring during the MHC-peptide complex
formation; moreover, treatment of B lymphocytes with both
anti-IgG and anti-IgM results in an enhanced presentation of
citrullinated antigens, abrogated by the addition of autophagy
inhibitors; in vivo, the same mechanism may be mediated by
RF [70].
Romero et al. demonstrated that membrane disruption
can cause intracellular citrullination.This group showed that
neutrophils treatedwith granzyme/perforinBor complement
membrane attack complex undergo necrosis; the loss of
membrane integrity led to a massive influx of Ca2+ and
to an uncontrolled activation of PAD enzymes. The so-
called hypercitrullination deriving from these events pro-
duces an elevated number of citrullinated proteins.Therefore,
it can be hypothesized that in vivo an immune response
directed to neutrophils could result in the formation of self-
citrullinated antigens with a subsequent breaking of tolerance
[71].
3.3. Smoking and Citrullination. Smoking is a risk factor
for the development of ACPA-positive RA, especially in
people who present HLA-DRB∗0104 allele [72]. This habit
can increase the formation of citrullinated proteins and
promote an activation of the immune system. Nanoparticles
inbreathed with tobacco smoke can lead to the activation
of PAD2 and PAD4 inside the cells [73]. Smoke effects
on the cells include upregulation of PAD2 expression and
subsequent citrullination [74].
To point out the crucial role of other predisposing factors
in the onset of RA, Bongartz et al. revealed that lung biopsies
of smokers that have developed lung cancer did not show any
intracellular protein citrullination, in contrast with the strong
intracellular protein citrullination detected in RA affected
smokers [75].
3.4. PAD Inhibitors. Recently, several authors studied
inhibitors of PAD for the treatment of RA. Cl-amidine, a
pan-PAD inhibitor, showed an efficacy in mice with CIA
in reducing severity of disease, synovial citrullination, and
histological joint damage [76]. Another PAD inhibitor, the
compound named YW3-56, showed a 5-fold increase in
PAD4 activity inhibition, if compared with Cl-amidine.
YW3-56 has been tested as anticancer drug, but its ability in
blocking PAD4 could make it a good candidate also for the
treatment of RA [77].
4. Carbamylation and Rheumatoid Arthritis
Carbamylation is a nonenzymatic PTM that consists in the
addition of a cyanate group (O=C=N−) on self-proteins
[78]. This reaction usually affects the atoms of nitrogen,
although a certain degree of carbamylation has also been
demonstrated on sulphur atoms [79]. Free nitrogen atoms in
proteins can be found at the N-terminus or in the side chain
of lysine and arginine. The most important carbamylation
detected in patient with RA is the lysine carbamylation: this
chemical process leads to the formation of homocitrulline,
a noncanonical amino acid, through the link of the carbon
atom of cyanate with the nitrogen atom of the lysine [80].
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Figure 3: Protein carbamylation: causes and consequences. Several conditions can shift the balance between urea and cyanate towards cyanate
production, enhancing in this way the process of protein carbamylation. This event results in systemic effects and production of anti-CarP
autoantibodies.
Cyanate required for carbamylation can be produced in
two different ways.
The first way is the spontaneous degradation of blood
urea. In fact, urea is in equilibrium with cyanate [81], and the
equilibrium in cyanate-urea ratio in vivo seems to oscillates
around 1 : 200 [82].
The second way consists in cyanate intake from the
external environment. Cyanate is found at a concentration
of about 200 parts-per-trillion by volume in urban air and
can be detected in both tobacco and biomass smoke [83];
potassium and sodium cyanate are used in several herbicides
[84]; finally, many foods (e.g., broccoli) possess a moderate
quantity of thiocyanate that, reacting with reactive oxygen
species, can be converted in cyanate [85, 86].
In healthy individuals, the concentration of blood cyanate
is about 50 nmol/L, an amount that is 1000 times lower than
the expected one, according to urea kinetic equilibrium [87].
For some authors, this alteration can be explained with a
sort of “physiological carbamylation” of N-terminus of blood
proteins [88].
Carbamylation is time dependent: structural proteins,
due to their slow turnover, are indeed much more likely to be
carbamylated, if compared to proteins with shorter half-life
[89].
Carbamylation of self-proteins causes a loss of the native
proteic structure and can lead to a break of tolerance, finally
resulting in the formation of anti-carbamylated proteins
(anti-CarP) autoantibodies (Figure 3). These autoantibodies
can be detected in RA patients. Inhibition assays demon-
strated that ACPA and anti-CarP are 2 different families of
autoantibodies [90].
Immunizationwith homocitrullinated peptides can cause
T and B cell mediated immune response against the synovial
membrane, and the intrarticular injection of homocitrulline-
containing peptides can result in the development of a mild
arthritis even in nonimmunized mice. Interestingly, in the
study of Mydel and coworkers it was demonstrated that
mice immunization with homocitrulline followed by the
intrarticular injection of citrullinated or homocitrullinated
peptides determined a severe arthritis in a higher percentage
of the first group (more than 90%), suggesting this an
unexpected response as a final linkage between alteration in
citrullination and severe arthritis development [91].
Anti-CarP autoantibodies can be detected in about 16%
of seronegative RA patients; their presence is correlated to
a more severe and erosive disease [90] and represents a
risk factor for developing RA in patients with inflammatory
arthralgia [92]. Anti-CarP autoantibodies have been detected
in RA patients’ sera before the clinical manifestation of
disease [93]. So, they appear to be a new useful tool in the
diagnosis and follow-up of RA.
5. Conclusion
PTMs are certainly implicated in the development of RA and
in several other autoimmune and nonautoimmune diseases.
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Nowadays, many aspects of RA pathogenesis have been
understood, thanks to the large number of studies focusing
on the role of PTMs in the induction of this disease. However,
none of the theories proposed to explain the exact aetiology
of RA is completely exhaustive. Every single PTM alteration
alone is not sufficient to ignite the disease, so overlap of
multiple alterations seems to be needed for the onset of RA
in predisposed patients.
The challenge for the future studies is to find a linkage
between the various PTM alterations that occur during the
development of RA, in order to identify possible steps leading
to the breaking of self-tolerance and to the clinical onset of
the disease. Improving knowledge in the pathogenesis of RA
could offer new suggestions for the development of more
effective drugs.
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